Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Leukemia, Myeloid, Acute 69Breast Neoplasms 51Carcinoma, Non-Small-Cell Lung 28Neoplasms 27Myelodysplastic Syndromes 27Advanced Solid Tumors 27Advanced Solid Tumor 26Prostatic Neoplasms 23Stomach Neoplasms 19Recurrence 18Multiple Myeloma 18Neoplasm Metastasis 17Carcinoma, Hepatocellular 17Ovarian Neoplasms 15Lung Neoplasms 15Pancreatic Neoplasms 14Uterine Cervical Neoplasms 13Solid Tumor 13Sarcoma 13Melanoma 13Leukemia, Myelomonocytic, Chronic 13Colorectal Neoplasms 11Triple Negative Breast Neoplasms 10Small Cell Lung Carcinoma 10Lymphoma, Large B-Cell, Diffuse 10Squamous Cell Carcinoma of Head and Neck 8Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

Injections 4toripalimab 3sintilimab 2Carboplatin 2aflutinib 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1Chlorogenic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Advanced Lung Cancer × Injections × Clear all
NCT07309276 2026-05-18

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
864 enrolled
Thoracic

Advanced Lung Cancer

NCT07367529 2026-05-05

A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
465 enrolled
Thoracic

Advanced Lung Cancer

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

NCT07229599 2025-11-17

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
300 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡